Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/20756
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBos, Wendy-
dc.contributor.authorWestra, Anna E.-
dc.contributor.authorPINXTEN, Wim-
dc.contributor.authorMayer, Matthew P.-
dc.contributor.authorLantos, John D.-
dc.date.accessioned2016-03-01T13:15:21Z-
dc.date.available2016-03-01T13:15:21Z-
dc.date.issued2015-
dc.identifier.citationPEDIATRICS, 136 (6), p. 1173-1177-
dc.identifier.issn0031-4005-
dc.identifier.urihttp://hdl.handle.net/1942/20756-
dc.description.abstractStudies of innovative therapies for muscular dystrophy raise unique ethical issues. The disease is currently untreatable and relentlessly progressive. A number of potentially efficacious treatments are being developed, but like all treatments, they may have unforeseen adverse effects. Nevertheless, patients and families, facing a bleak future, may be willing to take the gamble and try the treatments. Many doctors are eager to study them. But should institutional review boards approve them? This article discusses these issues and recounts the ways that one such study elicited different responses from different institutional review boards.-
dc.description.sponsorshipDr Lantos' work on this paper was supported by a CTSA grant from NCATS awarded to the University of Kansas Medical Center for Frontiers: The Heartland Institute for Clinical and Translational Research # UL1TR000001 (formerly # UL1RR033179). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS. ZonMW supplied support for Ms Bos for research at the Erasmus University Medical Center.-
dc.language.isoen-
dc.rightsCopyright © 2015 by the American Academy of Pediatrics-
dc.titleRisks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy.-
dc.typeJournal Contribution-
dc.identifier.epage1177-
dc.identifier.issue6-
dc.identifier.spage1173-
dc.identifier.volume136-
local.bibliographicCitation.jcatA1-
dc.description.notesLantos, JD (reprint author), Childrens Mercy Hosp, 2401 Gillham Rd, Kansas City, MO 64105 USA. jlantos@cmh.edu-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1542/peds.2015-1589-
dc.identifier.isi000370254400050-
item.fulltextNo Fulltext-
item.fullcitationBos, Wendy; Westra, Anna E.; PINXTEN, Wim; Mayer, Matthew P. & Lantos, John D. (2015) Risks in a Trial of an Innovative Treatment of Duchenne Muscular Dystrophy.. In: PEDIATRICS, 136 (6), p. 1173-1177.-
item.validationecoom 2017-
item.accessRightsClosed Access-
item.contributorBos, Wendy-
item.contributorWestra, Anna E.-
item.contributorPINXTEN, Wim-
item.contributorMayer, Matthew P.-
item.contributorLantos, John D.-
crisitem.journal.issn0031-4005-
crisitem.journal.eissn1098-4275-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.